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1. Introduction 
Breast cancer is a major challenge to current medicine; it is the disease with highest death 
rate in the female population and is even of significance to the male population. Although 
breast cancer is effectively treated by surgery at early stages, patients who present with 
breast cancer metastases at diagnosis or who subsequently develop metastatic disease have 
a much poorer prognosis. A feature of the normal breast endothelium is its regulation by the 
endocrine system; steroid hormones such as oestrogen are released predominantly by the 
ovary and control both proliferation and differentiation of epithelial cells. The proliferation 
of corresponding carcinoma cells that arise in early breast cancer has a similar dependence 
on endocrine hormones. Thus, one of the main methods for treating early breast cancer, 
apart from surgery, is to block the growth promoting action of oestrogen, either by blocking 
the downstream action with antioestrogens such as tamoxifen or by reducing the 
concentration of circulating oestrogen through oophorectomy or treatment with aromatase 
inhibitors. While such treatment is generally effective, the consequent emergence of 
aggressive tumours is common and poses a major barrier to successful disease management.  
Heterogeneity has been postulated to be a key property of both breast cancer and epithelial 
subtypes of normal breast tissue (Visvader, 2009). MCF-7, a commonly used breast cancer 
cell line, has been propagated for many years by multiple groups and it might be expected 
that such propagation would select a single phenotype that had the highest growth rate. 
However, the finding of extensive heterogeneity among MCF-7 lines used by different 
groups (Nugoli et al., 2003) suggests that mechanisms may be operating within proliferating 
MCF-7 populations to generate phenotypic diversity continuously. The aim of this chapter is 
to discuss the evidence of the way that the MCF-7 breast cancer cell line is heterogeneous 
with respect to both the expression of hormone receptors and to the utilization of the 
signalling pathways linked to these receptors. Such heterogeneity may be reflected by the 
presence of multiple phenotypes within a tumour population that differ markedly in their 
relative expression of receptors such as progesterone receptor (PR), oestrogen receptor (ER), 
epidermal growth factor receptor (EGFR) and epidermal growth factor receptor-2 (HER2; 
also known as ErbB2).  
2. Detection of cellular heterogeneity in the MCF-7 breast cancer cell line 
Several approaches have been employed to investigate phenotypic heterogeneity in MCF-7 
cell lines. Cassanelli et al. (1995) isolated a series of individual MCF-7 clones and measured 
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their expression of PR, finding that two thirds were PR-negative and that the remainder 
showed various degrees of PR expression. They also showed that PR expression was related 
to proliferation rate in culture. Coser et al. (2009) isolated multiple MCF-7 clones using two 
different culture conditions. Firstly, they picked individual colonies from low density MCF-
7 cultures to establish antioestrogen-sensitive MCF-7 sub-lines. Secondly, they picked 
individual antioestrogen-resistant colonies from MCF-7 cultures that had previously been 
grown to high density and exposed to either 4-hydroxytamoxifen (1 µM) or to fulvestrant 
(10–100 nM) for 21 days. The surviving cells (less than 0.001% of the population) were 
allowed to recover in drug-free growth medium for 7 days before isolation of the colonies, 
and all sub-lines subsequently characterized within a 20 population doubling period of 
culture. The isolated sub-lines could be distinguished by morphology, gene expression 
profile, gene copy number variations and the presence of individual genetic changes. The 
results indicated that all of the antioestrogen-resistant MCF-7 sub-lines were derived from a 
common ancestor. 
In a somewhat different approach, Leung et al. (2010) set out to mimic, in vitro, the 
conditions that lead to the development clinical resistance to antioestrogens (Leung et al., 
2010). Three different conditions were used to generate sub-lines. Firstly, MCF-7 cells were 
grown continuously in standard growth medium in the presence of increasing amounts of 
tamoxifen to produce the TamR7 sub-line. Oestrogen (which is present in foetal bovine 
serum) was not specifically excluded, thus mimicking clinical antioestrogen therapy. 
Secondly, cells were grown continuously in culture medium in the absence of both 
oestrogen and phenol red (which has oestrogenic properties) to produce the TamC3 and 
TamC6 sub-lines. The foetal bovine serum, used as a source of growth factors, had been 
previously absorbed with charcoal to remove oestrogen, thus mimicking the clinical effects 
of either oophorectomy or treatment with aromatase inhibitors such as letrozole. Thirdly, 
cells were grown continuously as above in the absence of oestrogen but with the addition of 
tamoxifen to produce the TamR3 and TamR6 sub-lines, thus mimicking the effect of 
combined therapy with antioestrogens plus aromatase inhibitors. Independent studies were 
undertaken using different batches of foetal calf serum, one batch giving the “3-series” 
(TamC3 and TamR3) and another giving the “6-series” (TamC6 and TamR6). Each condition 
resulted initially in the death of a high proportion of the cell population, followed over a 
period of at least 6 months by the emergence of resistant cells; however, the sub-lines were 
not clonally derived. Some of the properties of these sub-lines are shown in Table 1; all were 
shown by microsatellite analysis to be related to the parental MCF-7 cell line (Leung et al., 
2010). 
 
  Parental TamR7 TamC3 TamR3 TamC6 TamR6 
DNA content (ploidy) 1.5 1.9 1.4 1.4 2.0 2.1 
Modal cell volume (pL) 2.4 2.6 1.6 1.7 2.2 2.0 
Cell cycle time (hours) 31 31 27 27 36 37 
Table 1. Characteristics of the MCF-7 line and of its sub-lines. From previously published 
data (Leung et al., 2010). 
The above sub-lines were each found to be resistant to tamoxifen and were initially 
characterized by DNA content, cell cycle time and cell size. Flow cytometry was utilized to 
measure DNA content following staining of DNA with propidium bromide; cell size was 
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determined by forward scatter in a flow cytometer; cell cycle time was measured by a 
stathmokinetic method involving the arrest of cell division by the mitotic poison paclitaxel 
and subsequent measurement of the reduction in the incorporation of 3H-thymidine by the 
S-phase (Baguley et al., 1995). Surprisingly, DNA content alone distinguished four of the 
five sub-lines (Fig. 1). The parental MCF-7 line was aneuploid with a DNA content of 1.5x 
diploid, while the ploidy of derived sub-lines ranged from 1.4x diploid to 2.1x diploid. 
Changes in ploidy arise as a consequence of chromosomal instability, which in turn is 
related to the presence of extra centrosomes (Ganem et al., 2009). Control of centrosome 
number is in turn influenced by the expression of oncogenic and tumour suppressor 
proteins (Fukasawa, 2007). Changes in ploidy of a tumour population appear to occur 
gradually as a function of cell division, providing an effective measure of divergence of 
individual cells in a population.  
 
 
Fig. 1. Relationship between DNA ploidy, modal cell volume and cell cycle time of MCF-7 
sub-lines. Figure reproduced from previously published data (Leung et al., 2010). 
Mean cell cycle time and modal cell volume were also used to distinguish the sub-lines. 
Surprisingly, cell volume did not appear to be related to DNA content (Fig. 1). It was of 
interest that two lines, TamC6 and TamR6, which were derived under very different growth 
conditions (one in the presence of tamoxifen and one in its absence) showed very similar 
DNA content, cell cycle time and modal cell volume; the same situation applied to TamC3 
and TamR3, which are very similar to each other although differing substantially from 
TamC6 and TamR6 (Fig. 1). Although it is likely that the constituent cell lines in each of 
these pairs are not identical, their similar properties suggest they are closely related. Such 
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hierarchies might be expected on the basis of molecular signatures derived from gene 
expression arrays (Coser et al., 2009). 
3. Steroid hormone receptor expression 
The results in the previous section demonstrate the presence of heterogeneity in the MCF-7 
cell lines and imply that small sub-populations existing in the parental line can be expanded 
under appropriate selective conditions. The time scale of the in vitro selection process (6 
months or more) is consistent with the long period of time that occurs clinically in the 
development of resistance to antioestrogens or aromatase inhibitors in breast cancer 
patients. However, a critical question with regard to therapy is whether the emerging sub-
lines express altered receptors and associated signalling pathways. This question was 
addressed using the sub-lines in Table 1. Expression of ER is shown in Fig. 2 and that of PR 
is shown in Fig. 3. MCF-7 is an ER+ tumour but as can be seen from Fig. 2, ER expression 
was weak when compared to that of the tamoxifen-resistant sub-lines with the exception of 
TamC6, which also expressed ER weakly. On the other hand, expression of PR was strong in 
the parental line, weak in TamC6 and virtually absent in the remaining sub-lines. 
 
 
Fig. 2. Relative expression of ER, EGFR and HER2 by MCF-7 and its sub-lines in the absence 
(-) and presence (+) of tamoxifen (1 µM). Reproduced from previously published data 
(Leung et al., 2010). 
None of the tamoxifen-resistant lines showed complete absence of ER expression but this 
may have been a result of the selection method. Tamoxifen is a partial ER agonist, probably 
acting on ER associated with the plasma membrane and selection in the presence of 
tamoxifen may favour cells expressing ER. An alternative approach was carried out by Liu 
et al. (2006), who used fulvestrant as a “pure” antioestrogen for cell line selection. This 
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resulted in the generation of a MCF-7 sub-line (MCF-7/F) that did not express ER and that 
grew independently of either oestrogen or antioestrogens (Liu et al., 2006). 
4. Growth factor receptor expression 
The growth of breast cancer cells is controlled not only by ER and PR but also by plasma 
membrane-associated growth factor receptors. Two particularly important members of this 
large family are EGFR, which is activated by epidermal growth factor (EGF), and HER2. The 
expression of the two receptors was compared in MCF-7 cells and in their tamoxifen-
resistant sub-lines. EGFR was expressed very weakly in parental MCF-7 cells but was 
upregulated in the sub-lines with strongest expression in the TamR7 sub-line (Leung et al., 
2010). It was also upregulated in an MCF-7 sub-line (MCF-7/F) that does not express ER 
(Liu et al., 2006). Since EGFR is activated by phosphorylation, expression of the 
phosphorylated form of EGFR is more indicative of activity. As shown in Fig. 2, the parental 
and TamR7 cell lines show weak phosphorylation and TamC6 strong phosphorylation, 
while the other lines show intermediate phosphorylation (Leung et al., 2010). For most of the 
sub-lines, addition of tamoxifen increased EGFR phosphorylation, suggesting a relationship 
between ER and EGFR pathway utilization, in keeping with other studies implicating cross-
talk between these pathways in breast cancer (Johnston, 2010).  
 
 
Fig. 3. Relative expression of PR by MCF-7 and its sub-lines. 
Expression of the HER2 also varied across the cell lines. It was moderate in the parental 
MCF-7 line and TamR7, increased in TamC3 and TamR3, and low or absent in the TamC6 
and Tam R6 sub-lines (Fig. 2). Previously, it was reported that PAX2 played an important 
role in the HER2 expression (Hurtado et al., 2008) and that of two MCF-7 phenotypes 
identified in this study, one expressed HER2 but not PAX2, while the other expressing PAX2 
but not HER2. PAX2 is a paired box protein involved in lineage determination that is 
expressed during development and is commonly expressed in breast cancers (Muratovska et 
al., 2003). Hurtado et al. (2008) suggested that this inverse relationship arises because PAX2 
competes with ER and its co-activator SRC-3 for binding sites on the HER2 promoter, so that 
expression of PAX2 leads to repression of HER2 expression. While these two phenotypes are 
each evident in Fig. 2, a third phenotype expressing both HER2 and PAX2 proteins is also 
apparent as represented by TamC3 and TamR3. This suggests that the regulation of HER2 
expression is more complex and that HER2 can sometimes be co-expressed with PAX2.  
As discussed in the previous two sections, MCF-7 sub-lines demonstrate a wide divergence 
in the relative expression of ER, PR and HER2. It would be interesting to determine whether 
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a sub-line of MCF-7 exhibiting “triple negative” properties could be isolated using 
appropriate selection procedures; this might form a useful model for understanding triple 
negative breast cancers that are encountered in clinical practice. Thus, the generation of 
variants of a single cancer cell line might be able to recapitulate the development of multiple 
phenotypes in clinical cancer. 
 
 
Fig. 4. Simplified diagram of the main pathways involving ERK, AKT (PKB) and mTOR. 
5. Growth factor receptor pathways 
Growth factor receptors such as EGFR and HER2 largely signal through a common 
pathway; self-association of adjacent receptors leads through tyrosine kinase 
phosphorylation to the activation of the receptor complex and recruitment of a series of 
associated signalling proteins that include RAS, phosphoinositide-3-kinase (PI3K) and 
RAF, ultimately contributing to the control of proliferation and survival; a simplified 
summary of these pathways is shown in Fig. 4. Members of the GTPase RAS family of 
proteins activate both the PI3K and RAF proteins, which in turn activate three key 
pathways: AKT (PKB; protein kinase B), ERK (extracellular related kinase) and mTOR 
(mammalian target of rapamycin). RAF activates ERK through the intermediate kinase 
MEK (mitogen-activated protein kinase kinase), while mTOR activates p70S6K, which is 
involved in the regulation of protein synthesis. Some measure of the crucial significance 
of these pathways to cancer growth is indicated by the incidence of mutations of the genes 
which control these signalling proteins; in particular, mutations of PIK3CA, the gene 
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specifying PI3K, are found in 15-40% of patients with breast cancer (Isakoff et al., 2005) 
and a PIK3CA mutation is also found in MCF-7 cells. The impact of these mutations is to 
provide a decreased dependence on external stimulation of the pathways by growth 
factors such as EGF. Measurement of the utilization of the above pathways demonstrated 
considerable variation among the different MCF-7 sub-lines (Leung et al., 2010) and the 
results are summarized in Fig. 5. Utilization of the PI3K pathway can be assessed by 
phosphorylation of AKT; since the PIK3CA mutation and the gain of PIK3CA copy 
number in the MCF-7 cell line (Wu et al., 2005) lead to constitutive activation of PI3K, one 
might expect a high degree of AKT phosphorylation.  
 
 
Fig. 5. Relative expression of AKT and its phosphorylated form p-AKT, phosphorylated p-
p70S6K, ERK and phosphorylated form p-ERK. Data are shown for MCF-7 and its sub-lines 
in the absence (-) and presence (+) of tamoxifen (1 µM). Reproduced from previously 
published data (Leung et al., 2010). 
Surprisingly, two of resistant MCF-7 sub-lines, TamC3 and TamR3, show low levels of 
phosphorylation of AKT, suggesting a comparatively low level of utilization. Utilization 
of the RAF pathway was assessed by measurement of ERK phosphorylation and here the 
parental line, as well as the TamC3 and TamR3 sub-lines, exhibited low phosphorylation 
while TamC6 and TamR6 exhibited high utilization and TamR7 showed intermediate 
phosphorylation. Utilization of the mTOR pathway was assessed by measurement of 
phosphorylation of the downstream signalling molecules p70S6K. Here the parental line, 
as well as the TamC3, TamR3 and TamR7 sub-lines, exhibited low phosphorylation levels 
while the TamC6 and TamR6 show higher utilization. The wide divergence in pathway 
utilization among the different sub-lines, as well as a lack of correlation between pathway 
utilization and expression of ER, PR, EGFR and HER2, was a surprising aspect of this 
study.  
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6. Response of MCF-7 sub-lines to therapeutic agents 
It is clear from the previous section that the MCF-7 sub-lines vary considerably in their 
utilization of the AKT (PKB), ERK and mTOR signalling pathways. An important question 
arising from this observation is whether a high level of utilization of a particular pathway is 
related to sensitivity to inhibitors of this pathway. For instance, based on the data in Fig. 4, 
are the parental and TamC6 cell lines, which show higher phosphorylation of AKT than the 
other sub-lines, differentially susceptible to inhibitors of PI3K? Furthermore, do PI3K 
inhibitors differentially inhibit AKT phosphorylation in cell lines showing increased 
phosphorylation? It should be noted that MCF-7 cells have a PIK3CA mutation and the 
consequently activated PI3K activity makes them generally more sensitive to inhibitors of 
PI3K than other cell lines containing the wild type enzyme (Serra et al., 2008). 
Since there are currently no PI3K inhibitors in routine clinical use, the question of 
differential sensitivity to PI3K inhibition was addressed using NVP-BEZ235 and 
GSK2126458 (Leung et al., 2011). NVP-BEZ235 is currently being tested in phase I/II clinical 
trials in breast cancer patients with advanced disease while GSK2126458 is being evaluated 
in a phase I trial in patients with solid tumours or lymphoma1. Examination of drug 
inhibitory properties showed that at drug concentrations of 1 µM and 50 nM, respectively, 
the parental and TamR7 lines were the most sensitive while TamC6 and TamR6 were the 
most resistant (Fig. 6). Thus, drug sensitivity was not related to pathway utilization. The 
question of differential inhibition of AKT phosphorylation was also examined; the parental 
and TamR7 were the most sensitive while TamC6 and TamR6 were least sensitive (Leung et 
al., 2011). This correlated well with inhibition of cell proliferation. A subsequent 
commentary on this work emphasises the importance of understanding the principles 
underlying sensitivity and resistance to inhibitors of this pathway (Butt, 2011). 
A second example is provided by the mTOR pathway. Rapamycin is the classical inhibitor 
of this pathway and mTOR inhibitors such as everolimus and temsorolimus are in clinical 
trial. Moreover, treatment of mice with rapamycin sensitizes MCF-7 tumour xenografts to 
inhibition by tamoxifen (deGraffenried et al., 2004). Are MCF-7 sub-lines that highly 
phosphorylate the mTOR substrate p70S6K differentially sensitive to rapamycin? As 
measured by growth inhibition assays, the parental line and TamR7 were the most sensitive 
(Leung et al., 2010) while TamC6 and TamR6, where p70S6K are also highly 
phosphorylated, are resistant (Fig. 5). A third example is provided by the ERK pathway. No 
inhibitors of MEK, the enzyme that phosphorylates ERK, are yet in clinical use but CI-1040 
has undergone clinical trial. Are MCF-7 sub-lines that show high phosphorylation of ERK, 
the MEK substrate, differentially sensitive to CI-1040? This does not appear to be the case 
because TamC3 was the most sensitive to CI-1040 despite showing only moderate 
phosphorylation of the ERK protein (Fig. 5).  
Taken together, these results indicate a lack of a clear relationship between the degree of 
utilization of a particular pathway and the degree of dependence of cell growth on that 
pathway. While this may at first seem counter-intuitive, it should be kept in mind that 
phosphorylation pathways are utilized by the cell not only to promote proliferation but also 
to promote survival. Growth in culture in the presence of the multiple growth factors and 
antioxidants provided by foetal bovine serum is very different from growth in vivo, where  
 
                                                                 
1 http://clinicaltrials.gov/ct2/show/NCT00620594 and 
http://clinicaltrials.gov/ct2/show/NCT00972686. 
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Fig. 6. Relative effects of inhibitors of mTOR (rapamycin), MEK (CI-1040) and PI3K (NVP 
BEZ235 and GSK2126458). Asterisks represent significant increases (p < 0.05) and negative 
values indicate evidence of cell killing. The two lower graphs are reproduced from 
previously published data (Leung et al., 2011).  
the microenvironment is much more hostile. It is of interest in the case of the inhibitors of 
PI3K that the induction of apoptosis, if observed at all, was seen only at the highest drug 
concentrations tested, and that the main basis for inhibition of culture growth, particularly 
in the determination of IC50 values, was the induction of cell cycle arrest (Leung et al., 2011). 
It can thus be hypothesized that there are many alternative pathways that can be 
accentuated to promote cell survival and that different sub-lines have developed individual 
combinations of survival mechanisms. Only a small proportion of the overall signalling may 
be required to maintain cells in a proliferating state. 
7. Conclusion 
The hypothesis that emerges from these studies is that the human breast MCF-7 line, 
although often treated as a single entity, comprises a large number of individual 
phenotypes, most of which constitute only small proportions of the total population. These 
phenotypes differ in gene expression profile, receptor expression and signalling pathway 
usage. Despite differences in proliferation rate of individual phenotypes, a balance of 
multiple phenotypes is somehow maintained during progressive culturing of the line, 
perhaps by some type of signalling co-operation. The proportion of the dominant phenotype 
may be maintained by the growth conditions; in the case of MCF-7 the predominance of the 
ER+ phenotype could maintained by the presence of small amounts of oestrogen in the 
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foetal bovine serum. However, extended growth in the absence of oestrogen would select 
for variants that rely on EGFR, HER2 and other stimulators of signalling pathways.  
If the above hypothesis is correct, it raises three important questions. The first is whether 
such heterogeneity is a feature of all human breast cancer cell lines. Based on current 
literature, this is likely to be the case. Multiple antigenic phenotypes have been identified in 
several breast cancer cell lines (Edwards et al., 1985). Studies with T47D breast cancer cells 
using multidimensional flow cytometry have shown the presence of different phenotypes 
that differ not only in the expression of PR but also in DNA content (Graham et al., 1992). 
Further research is needed to explore the generality of these observations. 
The second question is whether human breast cancers growing in vivo show similar levels of 
heterogeneity to those of the derived cell lines. This question is difficult to answer unless 
individual cells can be identified, but evidence of heterogeneity of EGFR copy number has 
been detected in fine needle biopsies from 29 breast cancer patients, as well as in samples of 
the MCF-7, SKBR3, and T47D cell lines (Sauer et al., 2005). An answer to this question is 
critical because it could imply a common ancestry not only for breast cancer cells that differ 
in receptor status but also in histological status and growth rate. 
The third question is whether the mechanisms responsible for generating the heterogeneity 
of breast cancer cell types also apply to normal mammary tissue. There is increasing 
evidence for the existence of a differentiation hierarchy in the adult mammary epithelium, 
where precursor cells at various levels of the hierarchy are able to switch expression of 
proteins involved in differentiation; such switching includes the epidermal-mesenchymal 
transition (Visvader, 2009). The mechanism of such phenotype switching is not yet 
understood but is thought to involve epigenetic changes mediated by changes in DNA 
methylation, histone modification and concentrations of non-coding RNA (Huang & 
Esteller, 2010). These studies imply that the mechanism for generation of multiple 
phenotypes in breast cancer cells could be based on existing mechanisms that occur in the 
normal breast epithelium, with additional tumour-specific mechanisms arising from genetic 
alteration, chromosomal instability and possibly the presence of a mutated PI3K enzyme 
(Meyer et al. 2011). 
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